NASDAQ$TECH

Bio-Techne Corp · Q2 2022 earnings

Q2 2022 earnings · · Investor relations

Briefing

Bio-Techne's Q2 2022 earnings showcased strong growth, driven by operational excellence and strategic investments.

Bio-Techne reported a strong second quarter in fiscal year 2022, with a 20% increase in net sales to $269.3 million and organic revenue growth of 17%. The company's adjusted EPS increased to $1.88, and adjusted operating income rose by 18% to $102.8 million. The Protein Sciences segment demonstrated sustained operational excellence, achieving 19% organic growth.

  • Second quarter organic revenue increased by 17% (20% reported) to $269.3 million.
  • GAAP EPS was $1.94 versus $1.15 one year ago.
  • Adjusted EPS increased to $1.88 per diluted share, versus $1.62 in the same quarter last year.
  • Adjusted operating income for the second quarter of fiscal 2022 increased 18% compared to the second quarter of fiscal 2021.

Headline financials

Total Revenue

$269M

Previous: $224M+20.1%
EPS (adj)

$0.47

Previous: $0.41+14.6%
Capital Expenditures

-$16.2M

Previous: -$22.4M+27.5%
Free Cash Flow

$63.9M

Previous: $23.9M+167.6%
Net Income

$80.2M

Previous: $46.3M+73.3%
Operating Income

$62.3M

Previous: $51M+22.3%
Gross Profit

$184M

Previous: $151M+21.7%
Cash & Equivalents

$212M

Previous: $166M+28.0%
Total Assets

$2.3B

Previous: $2.07B+11.5%
Stock-Based Comp

$14M

Previous: $15.6M-10.3%

Revenue & EPS history

Bio-Techne · Revenue · Quarterly

$269M

Q2 2022+20.1%vs Q2 2021
Beat estimate in 13 of 16 quarters(81%)
ActualEstimate

Revenue by segment

Bio-Techne · $205M total across 1 segment · Q2 2022

  • Protein Sciences
    $205M+19.0%

Forward guidance

The Wilson Wolf future investment and acquisition agreement signed in December has the potential to further extend the company's 2026 revenue target beyond $2 billion and positions its Cell and Gene Therapy workflow with the strongest global footprint in this exploding new market.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2022

Historical avgQ2 2022

+0.8%

Avg return

Earnings day

+1.0%

Avg return

5 days after

+1.8%

Avg return

30 days after

58%

39 / 67 earnings

Positive

+19.6%

Q3 2024

Best reaction

-9.0%

Q1 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2026+0.0%-18.3%-8.1%
Q2 2026+4.8%+1.3%-16.6%
Q1 2026-1.9%-6.0%+0.9%
Q3 2025+2.2%+13.0%+2.0%
Q2 2025+3.7%-3.6%-11.3%
Q1 2025+4.3%+7.3%+6.5%
Q4 2024-6.4%-8.5%-8.8%
Q3 2024+19.6%+20.3%+22.1%
Q2 2024-6.2%-4.2%+5.8%
Q1 2024-6.7%+3.7%+11.1%
Q4 2023+2.1%+3.8%-9.0%
Q3 2023+4.8%+2.6%+3.5%
Q2 2023-2.6%-3.5%-3.7%
Q1 2023+0.6%+2.5%+16.7%
Q4 2022-2.3%-7.8%-15.8%
Q3 2022+0.7%-9.5%-5.3%
Q2 2022+11.0%+8.9%+11.5%
Q1 2022-3.9%-5.3%-11.0%
Q4 2021-1.0%-4.7%+5.4%
Q3 2021+1.5%-0.3%+1.8%
Q2 2021+8.3%+11.9%+2.3%
Q1 2021+13.2%+12.4%+14.8%
Q4 2020-3.9%-4.7%-10.1%
Q3 2020+7.7%+16.5%+25.4%
Q2 2020-0.3%-3.0%-6.4%
Q1 2020+0.0%+0.6%+6.1%
Q4 2019-4.6%-3.7%-4.8%
Q3 2019+3.0%+4.8%-0.7%
Q2 2019+5.3%+3.3%+7.3%
Q1 2019-5.5%-4.1%-8.5%
Q4 2018+5.0%+5.8%+12.8%
Q3 2018-2.8%-1.4%+0.1%
Q2 2018+3.0%+0.8%+8.6%
Q1 2018+3.8%+4.6%+9.0%
Q4 2017-1.5%+1.1%+3.8%
Q3 2017+2.0%+3.0%+5.3%
Q2 2017-1.0%+2.3%+6.2%
Q1 2017+0.3%-1.6%+4.3%
Q4 2016-3.4%-2.8%-2.6%
Q3 2016+7.1%
Q2 2016+4.9%
Q1 2016-9.0%
Q4 2015-2.3%
Q3 2015+1.6%
Q2 2015-3.2%
Q1 2015-2.8%
Q4 2014+0.2%
Q3 2014+8.1%
Q2 2014-4.4%
Q1 2014+0.7%
Q4 2013+4.1%
Q3 2013+0.4%
Q2 2013-2.2%
Q1 2013-4.3%
Q4 2012-3.8%
Q3 2012+0.5%
Q2 2012+2.2%
Q1 2012-5.3%
Q4 2009+1.4%
Q4 2011+1.4%
Q3 2011+0.5%
Q3 2010+0.5%
Q2 2011-0.8%
Q1 2011+0.6%
Q4 2010+0.6%
Q1 2010+0.6%
Q2 2010+0.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro